Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Carcinoma, Non-Small-Cell Lung 58Breast Neoplasms 43Prostatic Neoplasms 32Lung Neoplasms 29Multiple Myeloma 23Neoplasms 22Parkinson Disease 4, Autosomal Dominant Lewy Body 17Ovarian Neoplasms 17Colorectal Neoplasms 17Neoplasm Metastasis 16Leukemia, Lymphocytic, Chronic, B-Cell 16Carcinoma, Renal Cell 14Pancreatic Neoplasms 13Endometrial Neoplasms 12Small Cell Lung Carcinoma 11Urinary Bladder Neoplasms 10Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Myasthenia Gravis 9Lymphoma, Follicular 9Leukemia, Myeloid, Acute 9Fallopian Tube Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 8Colonic Neoplasms 8Burkitt Lymphoma 7Recurrence 6Lymphoma, Mantle-Cell 6Esophageal Neoplasms 6Adenocarcinoma 6Triple Negative Breast Neoplasms 5

Interventions

Lenalidomide 2dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Smoldering Multiple Myeloma × 30 days × Clear all
NCT00114101 2026-05-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡